Literature DB >> 3265081

Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study.

R F Dons1, P Rosselet, B Pastakia, J Doppman, P Gorden.   

Abstract

The medical records of 90 patients with acromegaly were reviewed. Arthralgias were noted in 76% of the patients with 17% having the onset of joint pain concomitant with the clinical onset of acromegaly. Of 47 patients followed prospectively for 5 or more years after pituitary irradiation, six (12.8%) were unaffected by arthralgias. A statistically higher mean baseline growth hormone level was found for the 19 (40.4%) radiotherapy patients who had severe and disabling arthropathy. Mean intervals between clinical onset of acromegaly and the development of arthropathic symptoms were shorter (4.1 years) for patients over 40 years of age and longer (9.7 years) for those under 31 years of age. Severely affected patients tended to have increased joint spaces in both weight-bearing and non-weight-bearing joints followed by a progressive decrease in joint spaces. Arthropathy is a common complication of acromegaly and may progress independently of a fall in growth hormone, induced by any form of treatment, once significant cartilage overgrowth develops. Cartilage overgrowth is a predisposing factor in the development of an arthropathy associated with the wide range of growth hormone levels characteristic of acromegaly.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3265081     DOI: 10.1111/j.1365-2265.1988.tb03686.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

1.  Acromegalic arthropathy.

Authors:  A L Barkan
Journal:  Pituitary       Date:  2001-09       Impact factor: 4.107

Review 2.  Acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

Review 3.  Rheumatic manifestations of pituitary tumors.

Authors:  S Stavrou; D L Kleinberg
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

Review 4.  Epidemiology of acromegaly.

Authors:  I M Holdaway; C Rajasoorya
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

Review 5.  Growth hormone in musculoskeletal pain states.

Authors:  Robert Bennett
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

6.  Gender-related differences in growth hormone-releasing pituitary adenomas. A clinicopathological study.

Authors:  Bernhard Schaller
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

7.  Ultrasonographic measurement of femoral cartilage thickness in acromegalic patients.

Authors:  Murat Karkucak; İbrahim Batmaz; Nadim Civan; Fatih Kilinc; Erhan Capkin; Mustafa Akif Sariyildiz; Melek Aslan Garipoğlu; Mustafa Avni Onder; Levent Ozcakar
Journal:  Clin Rheumatol       Date:  2014-02-27       Impact factor: 2.980

8.  Improvement of acromegaly after octreotide LAR treatment.

Authors:  Ruth Mangupli; Aponte Lisette; Contreras Ivett; Camperos Paul; Cruz de los Ríos Victoria; Cevallos Jose Luis
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

9.  Functional evaluation of the joints in acromegalic patients and associated factors.

Authors:  Leandro Lemgruber Kropf; Miguel Madeira; Leonardo Vieira Neto; Mônica Roberto Gadelha; Maria Lucia Fleiuss de Farias
Journal:  Clin Rheumatol       Date:  2013-03-13       Impact factor: 2.980

Review 10.  Growth hormone in musculoskeletal pain states.

Authors:  Robert Bennett
Journal:  Curr Pain Headache Rep       Date:  2005-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.